WNT5A and visceral leishmaniasis: In a very preliminary study comprising only a limited number of blood plasma samples collected from healthy individuals and patients with VL or PKDL (Post Kala-azar Dermal Leishmaniasis), we in fact noted, that healthy individuals and most of the patients either under treatment with miltefosine or with no symptom of VL had higher level of Wnt5A in their plasma than those with symptomatic VL or PKDL.